STAT Plus: A richly funded CRISPR alternative has a reproducibility problem
Back in 2016, a company called Homology Medicines came into the world with the claim that its scientists had built a better mousetrap for genome editing, using viruses to tinker with DNA in vivo instead of CRISPR’ing cells in a lab.
That brought millions in venture dollars, a $144 million IPO, and a nearly $1 billion market cap.
Continue to STAT Plus to read the full story…
Read Original Article: STAT Plus: A richly funded CRISPR alternative has a reproducibility problem »
